On Wednesday, December 19th, Roche/Genentech announced the US and Canadian locations for their upcoming study to test efficacy of the huntingtin-lowering therapy RG6042. This will be a 2-year study in people with early diagnosed HD. It will involve monthly lumbar punctures (spinal injections) to deliver RG6042 or a placebo, as well as clinical tests and scans to understand the effect of the drug on HD symptoms. Around 660 people age 25-65 will be recruited at approximately 90 sites across the world, including 20 in the US and 6 in Canada.
Read the full information release, including study sites, here.
Please note that sites have not yet begun recruiting, and that each site must obtain its own internal approval before formally beginning the study. Open sites will be listed at www.hdtrialfinder.org and at the government’s clinical trials website: https://clinicaltrials.gov/ct2/show/study/NCT03761849
As a reminder, HDSA does not control participation in this trial, and recruitment is likely to take place through existing doctor/patient relationships. Roche/Genentech has also provided a Clinical Trial Information Support Line at 1-888-662-6728 (reference study ID number BN40423).
Detailed information about this study was also presented by Roche in a recent HDSA Webinar and in an HDSA FAQ document.
There’s a long way to go to determine whether the drug is effective, but we’re very excited to be able to share this milestone with the community.
2018 Research Year in Review Webinar
To complement our 2018 Research Report, George and Leora will be sharing this year’s HD research highlights in our 2018 Research Year in Review Webinar on Wednesday, January 16th, 2019, from 12-1 pm Eastern time.
Register to attend the webinar here.
